Arthur Krieg to Drug Administration Schedule
This is a "connection" page, showing publications Arthur Krieg has written about Drug Administration Schedule.
Connection Strength
0.040
-
Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res. 2007 Oct 15; 13(20):6168-74.
Score: 0.017
-
Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Laframboise C, Leese P, Krieg AM, Efler SM, Davis HL. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007; 12(5):741-51.
Score: 0.016
-
Steinberg AD, Krieg AM, Takashi T, Gourley MF. Timing of immunosuppression in the natural history of autoimmune diseases. J Autoimmun. 1992 Apr; 5 Suppl A:197-203.
Score: 0.006